CureDuchenne Ventures Invests in MyoGene Bio and its AAV-Delivered CRISPR/Cas9 Gene Editing Approach

NEWPORT BEACH, Calif., May 11, 2023 /PRNewswire/ — CureDuchenne Ventures announced funding for MyoGene Bio, LLC, a biotech company developing a novel gene editing therapy for Duchenne muscular dystrophy (DMD). MyoGene will use this funding to advance development of MyoDys45-55, an…